Canada's NeuPath Health Q4 revenue rises on increased patient visits, new services

Overview

• Canada pain clinic operator's Q4 revenue rose 17% yr/yr

• Adjusted EBITDA for Q4 increased 9% yr/yr, marking 28th consecutive positive quarter

• Clinic revenue growth driven by more patient visits, new services, and improved physician utilization

Outlook

• NeuPath expects continued growth and margin improvement in 2026

• Company plans to expand to new locations and increase availability of Arthrosamid procedures

• NeuPath will report physical capacity utilization metrics quarterly starting in 2026

Result Drivers

• PATIENT VOLUME - Increased patient visits drove higher clinic revenue, according to the company

• NEW SERVICES - Launch of Arthrosamid and growth from fluoroscopy procedures contributed to revenue growth

• PHYSICIAN UTILIZATION - Improved physician utilization and capacity optimization supported revenue gains

Company press release: ID:nBw5mZYS9a

Key Details

Analyst Coverage

• The one available analyst rating on the shares is "buy"

• The average consensus recommendation for the healthcare facilities & services peer group is "buy"

• Wall Street's median 12-month price target for NeuPath Health Inc is C$0.50, about 4.2% above its March 25 closing price of C$0.48

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.